The Journal of Immunology, Vol 155, Issue 3 1382-1392, Copyright © 1995 by American Association of Immunologists

ARTICLES

T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3- associated kinases are present

Q Wang, J Stanley, S Kudoh, J Myles, V Kolenko, T Yi, R Tubbs, R Bukowski and J Finke
Department of Immunology, Cleveland Clinic Foundation, OH 44195, USA.

Although tumor infiltrating lymphocytes (T-TIL) from B cell non- Hodgkins lymphoma patients contain tumor-reactive T cells, they display poor proliferation and IFN-gamma production when stimulated through the TCR-CD3. To determine if there was altered signaling linked to TCR-CD3 ligation, tyrosine phosphorylation was examined in T-TIL because it represents an early and critical event in T cell activation. After stimulation with anti-CD3 Ab, Western blotting with anti- phosphotyrosine showed reduced phosphorylation in T-TIL when compared with peripheral blood-derived T cells from normal individuals. The altered phosphorylation was not due to the reduced expression of signaling elements linked to the TCR-CD3 complex. T-TIL expressed normal levels of CD3 epsilon, TCR zeta chain, and the three tyrosine kinases, p56lck (Lck), p59fyn, and ZAP-70. However, in T-TIL, anti-Lck Ab reacted with a 60-kDa protein, which appears to be the phosphorylated form of Lck. Binding of anti-Lck Ab to the 60-kDa protein was blocked by Lck peptide. In addition, anti-Lck Ab immunoprecipitated a phosphorylated 60-kDa protein from gamma-32P- labeled T-TIL that was not seen in normal resting T cells. In vitro kinase assay studies also demonstrated that TCR-CD3 engagement increased the kinase activity of Lck in normal T cells but not in T- TIL. These results suggest that although T-TIL from B cell non-Hodgkins lymphoma patients contain the signal transduction molecules associated with TCR-CD3 activation pathway, they are impaired in tyrosine phosphorylation and Lck activity, which may contribute to the functional defects of these cells.

This article has been cited by other articles:

				Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma. Cancer Res., October 15, 2006; 66(20): 10145 - 10152. [Abstract] [Full Text] [PDF]

				W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF]

				T. Y. Shibuya, N. Nugyen, C. E. McLaren, K.-T. Li, W.-Z. Wei, S. Kim, G. H. Yoo, A. Rogowski, J. Ensley, and W. Sakr Clinical Significance of Poor CD3 Response in Head and Neck Cancer Clin. Cancer Res., March 1, 2002; 8(3): 745 - 751. [Abstract] [Full Text] [PDF]

				S. G. Agrawal, J. Marquet, J. Plumas, H. Rouard, M.-H. Delfau-Larue, P. Gaulard, L. Boumsell, F. Reyes, A. Bensussan, and J.-P. Farcet Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue Int. Immunol., April 1, 2001; 13(4): 441 - 450. [Abstract] [Full Text] [PDF]

				S. M. Ansell, M. Stenson, T. M. Habermann, D. F. Jelinek, and T. E. Witzig CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin's Lymphoma Predicts Patient Outcome J. Clin. Oncol., February 1, 2001; 19(3): 720 - 726. [Abstract] [Full Text] [PDF]

				S. Radoja, T. D. Rao, D. Hillman, and A. B. Frey Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo J. Immunol., March 1, 2000; 164(5): 2619 - 2628. [Abstract] [Full Text] [PDF]

				C. Maccalli, P. Pisarra, C. Vegetti, M. Sensi, G. Parmiani, and A. Anichini Differential Loss of T Cell Signaling Molecules in Metastatic Melanoma Patients' T Lymphocyte Subsets Expressing Distinct TCR Variable Regions J. Immunol., December 15, 1999; 163(12): 6912 - 6923. [Abstract] [Full Text] [PDF]

				R. M. Bukowski, P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, et al. Interferon-{{gamma}} and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma Clin. Cancer Res., October 1, 1999; 5(10): 2780 - 2789. [Abstract] [Full Text] [PDF]

				V. Kolenko, T. Bloom, P. Rayman, R. Bukowski, E. Hsi, and J. Finke Inhibition of NF-{kappa}B Activity in Human T Lymphocytes Induces Caspase-Dependent Apoptosis Without Detectable Activation of Caspase-1 and -3 J. Immunol., July 15, 1999; 163(2): 590 - 598. [Abstract] [Full Text] [PDF]

				V. Kolenko, P. Rayman, B. Roy, M. K. Cathcart, J. O'Shea, R. Tubbs, L. Rybicki, R. Bukowski, and J. Finke Downregulation of JAK3 Protein Levels in T Lymphocytes by Prostaglandin E2 and Other Cyclic Adenosine Monophosphate-Elevating Agents: Impact on Interleukin-2 Receptor Signaling Pathway Blood, April 1, 1999; 93(7): 2308 - 2318. [Abstract] [Full Text] [PDF]

				R. E. Felgar, K. R. Steward, J. B. Cousar, and W. R. Macon T-Cell-Rich Large-B-Cell Lymphomas Contain Non-Activated CD8+ Cytolytic T Cells, Show Increased Tumor Cell Apoptosis, and Have Lower Bcl-2 Expression Than Diffuse Large-B-Cell Lymphomas Am. J. Pathol., December 1, 1998; 153(6): 1707 - 1715. [Abstract] [Full Text] [PDF]

				W. Ling, P. Rayman, R. Uzzo, P. Clark, H. J. Kim, R. Tubbs, A. Novick, R. Bukowski, T. Hamilton, and J. Finke Impaired Activation of NFkappa B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, Ikappa Balpha Blood, August 15, 1998; 92(4): 1334 - 1341. [Abstract] [Full Text] [PDF]

				C. J. Fitzer-Attas, D. G. Schindler, T. Waks, and Z. Eshhar Harnessing Syk Family Tyrosine Kinases as Signaling Domains for Chimeric Single Chain of the Variable Domain Receptors: Optimal Design for T Cell Activation J. Immunol., January 1, 1998; 160(1): 145 - 154. [Abstract] [Full Text] [PDF]

				D. M. Dorfman, J. L. Schultze, A. Shahsafaei, S. Michalak, J. G. Gribben, G. J. Freeman, G. S. Pinkus, and L. M. Nadler In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation Blood, December 1, 1997; 90(11): 4297 - 4306. [Abstract] [Full Text] [PDF]

				J. L. Schultze, M. J. Seamon, S. Michalak, J. G. Gribben, and L. M. Nadler Autologous Tumor Infiltrating T Cells Cytotoxic for Follicular Lymphoma Cells Can Be Expanded In Vitro Blood, May 15, 1997; 89(10): 3806 - 3816. [Abstract] [Full Text] [PDF]

				A. Guarini, L. Riera, A. Cignetti, L. Montacchini, M. Massaia, and R. Foa Transfer of the Interleukin-2 Gene Into Human Cancer Cells Induces Specific Antitumor Recognition and Restores the Expression of CD3/T-Cell Receptor Associated Signal Transduction Molecules Blood, January 1, 1997; 89(1): 212 - 218. [Abstract] [Full Text] [PDF]